Researchers from Zhejiang University of Technology and collaborators presented the discovery and preclinical characterization of YSA-64, a novel RBM39 degrader, in cancer models.
The University of Oxford and Moderna Inc. have announced authorization by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II study of mRNA-4194, Moderna’s investigational mRNA-based cancer vaccine for Lynch syndrome.
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help identify people who could benefit from preventive drugs. Published in Cell, the study was a collaboration between the Francis Crick Institute and University College London. It was co-led by Walter and Eliza Hall Institute laboratory head Clare Weeden, who conducted the research while at the Crick.
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors potentially useful for the treatment of cancer, pain, fibrosis and inflammatory disorders.
Onkure Therapeutics Inc. has disclosed new benzopyridinones acting as phosphatidylinositol 3-kinase α (PI3Kα) mutant inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities, scoliosis and PIK3CA-related overgrowth spectrum (PROS).
Hansoh Pharmaceutical Group Co. Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for HS-10541 tablets.
Amphista Therapeutics Ltd. has obtained IND clearance from the FDA for AMX-883, an orally bioavailable degrader of BRD9, for the treatment of acute myeloid leukemia (AML). A phase I trial in patients with relapsed or refractory AML and high-risk myelodysplastic syndrome is expected to begin in the second half of this year.
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged new mitogen-activated protein kinase (MAPK) inhibitors found to be potentially useful for the treatment of cancer.
RSS
